Controverses sur le dépistage et la prise en charge des dyslipidémies familiales en 2020 [Controversies concerning screening and treatment of primary dyslipidemias in 2020]

Details

Serval ID
serval:BIB_24A64741D9AA
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Controverses sur le dépistage et la prise en charge des dyslipidémies familiales en 2020 [Controversies concerning screening and treatment of primary dyslipidemias in 2020]
Journal
Revue medicale suisse
Author(s)
Bretagne L., Aubert C., Nanchen D., Rodondi N.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
04/03/2020
Peer-reviewed
Oui
Volume
16
Number
684
Pages
433-437
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
Familial dyslipidemia is rare compared to polygenetic causes. Nevertheless, it is important not to miss this diagnosis, as it is more strongly associated with an increased risk of early cardiovascular disease and scores for calculating cardiovascular risk are not valid in this population. Early detection and management based on lifestyle optimization and treatment of cardiovascular risk factors can delay the onset of cardiovascular complications and thus improve patients' quality of life. A LDL-Cholesterol of 4,9 mmol/l has recently been suggested as the cut-off for starting lipid lowering therapy, but remains controversial because the majority of people above this threshold do not have primary monogenic dyslipidemia. The age at which therapy should be initiated as well as the targets for treatment are also controversial.
Keywords
Cholesterol, LDL/blood, Dyslipidemias/blood, Dyslipidemias/diagnosis, Dyslipidemias/genetics, Dyslipidemias/therapy, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use, Quality of Life, Risk Factors
Pubmed
Create date
19/03/2020 17:29
Last modification date
03/02/2021 7:26
Usage data